<SEC-DOCUMENT>0001193125-22-142292.txt : 20220506
<SEC-HEADER>0001193125-22-142292.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160613
ACCESSION NUMBER:		0001193125-22-142292
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220505
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		22896167

	BUSINESS ADDRESS:	
		STREET 1:		55TH-56TH FLOOR, NEW BUND CENTER
		STREET 2:		555 WEST HAIYANG ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200124
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		55TH-56TH FLOOR, NEW BUND CENTER
		STREET 2:		555 WEST HAIYANG ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200124
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d337794d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of May 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>55th &#150;
56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 200124 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Long</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Long</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director and Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;5, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d337794dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g337794dsp01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Provides Updates on Status under Holding Foreign Companies
Accountable Act </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI and GAITHERSBURG, MD. May&nbsp;5, 2022</B> &#150; I-Mab (&#147;I-Mab&#148; or the &#147;Company&#148;) (Nasdaq: IMAB), a
clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign Companies Accountable Act (the &#147;HFCAA&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is aware that the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) provisionally identified I-Mab as a &#147;Commission-Identified
Issuer&#148; after the Company filed its annual report on Form 20-F for the fiscal year ended December&nbsp;31, 2021 with the SEC on April&nbsp;29, 2022, which included an audit report issued by a public accounting firm that the Public Company
Accounting Oversight Board (the &#147;PCAOB&#148;) has determined that it is unable to inspect completely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT>
understands that the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder, which will not directly result in the delisting of the Company&#146;s American Depositary Shares (&#147;ADSs&#148;) from Nasdaq.
Pursuant to the HFCAA, the SEC will prohibit a company&#146;s shares or ADSs from being traded on a national stock exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> trading market in
the United States if the Company has been identified by the SEC for three consecutive years due to the PCAOB&#146;s inability to inspect the registered public accounting firm&#146;s working paper related to such company.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> is in the process of engaging a selected U.S.-based independent registered public accounting firm as its
principal auditor that is subject to the inspection by the PCAOB. This firm also needs to comply with the applicable rules and regulations concerning information confidentiality and archives administration for compliance purposes in China. The
Company aims to complete the engagement in the second half of 2022 and subsequent change of its principal auditor is expected to take place in conjunction with the filing of its annual report for the fiscal year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The
Company&#146;s mission is to bring transformational medicines to patients around the world through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 20 clinical and preclinical-stage drug
candidates is driven by its internal discovery and global partnerships for <FONT STYLE="white-space:nowrap">in-licensing,</FONT> based on the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies. The Company
is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&amp;D capabilities, a world-class GMP manufacturing facility, and commercial capability. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit
<U><FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U>, and <U>WeChat</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g337794dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes certain disclosures which contain &#147;forward-looking statements.&#148; You can identify forward-looking statements because they
contain words such as &#147;will,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;future,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;estimates,&#148; and &#147;aims.&#148; Forward-looking statements are based
on <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ
materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from
those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT>
Contacts </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">John Long</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">IR@i-mabbiopharma.com</FONT></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Communications Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">PR@i-mabbiopharma.com</FONT></U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g337794dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g337794dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)JEXTTK[F[*.BCTKXK,,-BX_O<1&R;''$0K.T605Y>QJ]C6\)V!N-<60KF.
M%R??M_GVKV,LI>TK<SZ$TE[YZ/7U1V%'6II+?0]0FB8I+';R.K#L0I(-..Y,
MOA,#3[UO[7L4BO=5=9682+>V^Q"-C'@E!SD#@'IFMIQ23V,(2=U:XEG?7]_:
M:;;M>RQ-<7-TLDL87?M1W"J,@XZ#MVI2BDW\BHR;2)+Z:]TH:K"FH33A=.>X
MB:7:6C=<C@@#/;KZ4))I.W4&W%M-]""SO9!>Z4+/5KR]:=\3QR(&14V$DDA1
MMYQW]J4MFK"C>Z=R67Q+Y.BWP9+TW,1G"R+:2%00S!?F"XP,#FG[*\EJ'M.6
M+T+^K3WDFGV5E9W/D7MX5'F@ E% W,V/H,?5A4P2NV]BY-I66Y3U+5[H^"5O
MC(UK=;XHYBG)C;S520#K_M"B,?>L)R]RX_3+L-JK06^J75Y#]G=W%PH&Q@5"
MD':/5O7I3:NKM#B[.R96T?7;JW\.3&ZD-YJ,44<D8;"F;S0#&./]HE<_[-.<
M$WIL1";4==R72=5O+3PC>7=[(UY=6TT\8X ,C+(55>/4X%*<%SI1*C-\K<C0
M\/SW48N=.U"Y,]Y;%6+D %E<9!X[ [E_X#2FENATV]F;=9FHAH \>^*G@N6.
MX?Q'ID)=&'^EQKR0?[X'IZ_GZUZ.$K\ON2/,Q>'YO?B<=X7N1+%/'D9!!Q[?
MY%>M3=SPJ\+'05J<P=*0RW9+]YOPKXCBJO%JG13VN_R/6RVFU>;+L4,D\RQ1
M*7=CA0.]?%*,I/E@CV4KGHN@Z2-*L A(,SG=(1Z^GX5]G@\,L-3MU-H1L:O>
MNTL@OK5;VPN+1V*K/&T9*]0",52T$]3/@T:Y6ZMY;K5I[E(&W)&T<:C=@C)(
M /0FFY;V(4;6\B,>'$CM+:*WO9H9;::2:.50I.79BP((P1\Q_(4W4NP]G9:"
MGP^9DOOMFH37$EW;FV+%578AST 'OW]*7/T0.&]S6AA$,$<0)(10H)]JEO4I
M1L51I<8TF?3_ #&V3"0%NXWDD_\ H55S/FN'*N6Q7N/#MC>7<-Q=I]H,$/DQ
MJ_1>02?J<#\J.=I61+IIN[(1X7M$LKFSBEDCMYKA+@(N,(RE3@>Q*Y/U--S;
M=P5-)61IR6227L=T6(:.)X@.Q#%2?_0!4WT*Y5>YG#PS:"?2IC)(6TZ,1KTQ
M( ,+N]<')'N:KG=FNY/(KI]@/AJV>T%I)+(]N;M[IT.,.68MM/L&(/X"FJC3
MN)TTU8GM-"LK#4!>6<0@;RS&ZH.'&01GZ<X^IJ>=M692@D[HU*DL* $*JP(8
M @]C0!Y[J?PPLCJC:GHCBS=P?,MR/W;9YR/[I_2N^CC)0^+5'FXG QJQ]S1G
M.:CI-YI3A+R,(3T(8$'\J]>E6C5UB?/5J,Z+M(72-+FUF]%M 0.[,?X1Z^].
MO55"/-(K#T'B)6BSNV\$V@51!<R1[0 01N!]Z^#QF7+%U76<W=GU,,/&G!1B
M:NE:'::4N8P7F(P9&Z__ %JVPN!I8;;5]S:,;&J*[T4% !0 8H * "@ H *
M"@ H * "@ Q2L 4P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
* H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
